Orion Corp - Company Profile
Powered by 
All the sales intelligence you need on Orion Corp in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Orion Corp fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Orion Corp.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Orion Corp (Orion) develops, manufactures and markets human and veterinary pharmaceuticals, and active pharmaceutical ingredients (APIs). Its products include pharmaceuticals for the treatment of central nervous system disorders, cancer, and respiratory diseases. The company's pipeline encompasses investigational candidates for the treatment of Parkinson’s disease, chronic obstructive pulmonary disease, and various cancer types. . The company sells its products in European markets through its sales network and in international markets through several partners and distributors. Orion’s client base consists of healthcare service providers and professionals, such as doctors, pharmacies, veterinarians, hospitals, and laboratories. Orion operates production sites in Finland, France, and Belgium, with research centers in Finland, the UK, and the US. Orion is headquartered in Espoo, Finland.
Headquarters
Finland
Address
Orionintie 1A, Espoo, 02200
Website
www.orionpharma.com
Telephone
358 10 4261
No of Employees
4,235
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ORNBV (HEL)
Revenue (2024)
$2.1B
22.5%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
51.7%
(2024 vs 2023)
Market Cap*
$12.6B
Net Profit Margin (2024)
XYZ
23.8%
(2024 vs 2023)
* As of and is in US$
Orion Corp premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Medicines and self-care products: | - |
| Nubeqa (darolutamide) | Domitor |
| Stalevo (levodopa, karbidopa, entacapone) | Comtess |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In May, the company secured approval from the US Food and Drug Administration for the Tessie product (tasipimidine oral solution). |
| 2026 | Regulatory Approval | In April, the company secured orphan drug designation from the US Food and Drug Administration for its ODM-212 for the treatment of mesothelioma to treat cancer. |
| 2026 | Contracts/Agreements | In March, the company entered a strategic content partnership for 2026 with CMI - Martti Ahtisaari Peace Foundation. |
Competitor Comparison
| Key Parameters | Orion Corp | Merck & Co Inc | Abbott Laboratories | GSK plc | Biohit Oyj |
|---|---|---|---|---|---|
| Headquarters | Finland | United States of America | United States of America | United Kingdom | Finland |
| City | Espoo | Rahway | Abbott Park | London | Helsinki |
| State/Province | - | New Jersey | Illinois | England | - |
| No. of Employees | 4,235 | 75,000 | 115,000 | 66,841 | 48 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Veli-Matti Mattila | Chairman | Executive Board | 2024 | 65 |
| Liisa Hurme | Chief Executive Officer; President | Senior Management | 2022 | 59 |
| Rene Lindell | Chief Financial Officer | Senior Management | 2024 | 50 |
| Hilpi Rautelin | Vice Chairman | Executive Board | 2012 | 65 |
| Satu Ahomaki | Executive Vice President - Generics and Consumer Health | Senior Management | 2025 | 60 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer